Journal article
Population Prevalence of Personality Disorder and Associations with Physical Health Comorbidities and Health Care Service Utilization: A Review
SE Quirk, M Berk, AM Chanen, H Koivumaa-Honkanen, SL Brennan-Olsen, JA Pasco, LJ Williams
Personality Disorders Theory Research and Treatment | Published : 2016
DOI: 10.1037/per0000148
Abstract
Personality disorder (PD), outcomes of diverse comorbid physical health conditions, and the associated burden on health service resources have seldom been studied at a population level. Consequently, there is limited evidence that might inform a public health approach to managing PD and associated mental and physical disability. A review was conducted of population-based studies examining the prevalence of PD and associations between physical comorbidities and service utilization. The prevalence of any PDs were common (4.4% = 21.5%) among populations spanning England, Wales, Scotland, Western Europe, Norway, Australia, and the United States. Preliminary evidence supports associations between..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) of Australia Postgraduate Scholarship
Awarded by NHMRC
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
Shae E. Quirk was supported by a National Health and Medical Research Council (NHMRC) of Australia Postgraduate Scholarship (Grant 1076347). Michael Berk has received grant/research support from the National Institute of Health (USA), Simons Foundation, CRC for Mental Health, Stanley Medical Research Institute, Medical Benefits Fund, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay, and Wyeth, and is supported by a NHMRC Senior Principal Research Fellowship (Grant 1059660). Andrew M. Chanen has received research funding from the NHMRC, Australian Research Council, Colonial Foundation, the University of Melbourne, and the New South Wales Department of Health. Sharon L. Brennan-Olsen has received Grant/Research support from The University of Melbourne, Deakin University, Arthritis Australia, Arthritis Victoria, Australian Association of Gerontology, and Barwon Orthopaedic Research Trust, and is supported by an Alfred Deakin Postdoctoral Research Fellowship. Julie A. Pasco has received Grant/Research support from the NHMRC, BUPA Foundation, Deakin University, Barwon Health and the Western Alliance and has received speaker fees from Amgen and Sanofi Aventis. Lana J. Williams has received grant/research support from Eli Lilly, Pfizer, the University of Melbourne, Deakin University, the NHMRC, and is supported by a NHMRC Career Development Fellowship (Grant 1064272).